SG11201601850YA - Therapeutics targeting truncated adenomatous polyposis coli (apc) proteins - Google Patents
Therapeutics targeting truncated adenomatous polyposis coli (apc) proteinsInfo
- Publication number
- SG11201601850YA SG11201601850YA SG11201601850YA SG11201601850YA SG11201601850YA SG 11201601850Y A SG11201601850Y A SG 11201601850YA SG 11201601850Y A SG11201601850Y A SG 11201601850YA SG 11201601850Y A SG11201601850Y A SG 11201601850YA SG 11201601850Y A SG11201601850Y A SG 11201601850YA
- Authority
- SG
- Singapore
- Prior art keywords
- apc
- proteins
- adenomatous polyposis
- polyposis coli
- therapeutics targeting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0679—Cells of the gastro-intestinal tract
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/04—Immortalised cells
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361875933P | 2013-09-10 | 2013-09-10 | |
US201461930754P | 2014-01-23 | 2014-01-23 | |
PCT/US2014/054987 WO2015038644A2 (en) | 2013-09-10 | 2014-09-10 | Therapeutics targeting truncated adenomatous polyposis coli (apc) proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201601850YA true SG11201601850YA (en) | 2016-04-28 |
Family
ID=52666505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201601850YA SG11201601850YA (en) | 2013-09-10 | 2014-09-10 | Therapeutics targeting truncated adenomatous polyposis coli (apc) proteins |
Country Status (16)
Country | Link |
---|---|
US (2) | US9856233B2 (es) |
EP (1) | EP3044218B1 (es) |
JP (1) | JP6506291B2 (es) |
KR (2) | KR102300576B1 (es) |
CN (1) | CN105873913B (es) |
AU (2) | AU2014318821B2 (es) |
BR (1) | BR112016005252A2 (es) |
CA (1) | CA2924062C (es) |
DK (1) | DK3044218T3 (es) |
ES (1) | ES2811090T3 (es) |
HK (1) | HK1224291A1 (es) |
MX (1) | MX2016003082A (es) |
RU (1) | RU2727516C2 (es) |
SG (1) | SG11201601850YA (es) |
WO (1) | WO2015038644A2 (es) |
ZA (2) | ZA201601798B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3044218B1 (en) * | 2013-09-10 | 2020-05-27 | Board Of Regents Of the University Of Texas System | Therapeutics targeting truncated adenomatous polyposis coli (apc) proteins |
US10082496B2 (en) | 2014-09-10 | 2018-09-25 | Board Of Regents Of The University Of Texas System | Targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis |
EP3322417B1 (en) * | 2015-07-15 | 2023-08-23 | The Board of Regents of The University of Texas System | Targeting emopamil binding protein (ebp) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis |
EP3426654B1 (en) | 2016-03-09 | 2021-10-20 | President and Fellows of Harvard College | Direct palladium-catalyzed aromatic fluorination |
WO2018022904A2 (en) | 2016-07-27 | 2018-02-01 | Case Western Reserve University | Compounds and methods of promoting myelination |
US10918610B2 (en) | 2017-12-22 | 2021-02-16 | Case Western Reserve University | Compounds and methods of promoting myelination |
CN108250111B (zh) * | 2018-01-15 | 2020-04-28 | 华南理工大学 | 一种双受体有机发光小分子材料及其制备方法和应用 |
WO2020117972A1 (en) * | 2018-12-04 | 2020-06-11 | The Board Of Regents Of The University Of Texas System | Therapeutics targeting mutant adenomatous polyposis coli (apc) for the treatment of cancer |
CN113624665A (zh) * | 2021-07-30 | 2021-11-09 | 中国药科大学 | 一种抗肿瘤候选化合物在治疗结直肠癌药物中的应用及测定方法 |
WO2024020156A1 (en) * | 2022-07-22 | 2024-01-25 | Biogen Ma Inc. | Emopamil-binding protein inhibitors and uses thereof |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1521000A (en) | 1975-06-13 | 1978-08-09 | Syntex Puerto Rico Inc | Inhalation device |
US4227522A (en) | 1978-09-05 | 1980-10-14 | Syntex Puerto Rico, Inc. | Inhalation device |
US4192309A (en) | 1978-09-05 | 1980-03-11 | Syntex Puerto Rico, Inc. | Inhalation device with capsule opener |
US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
GR79615B (es) | 1982-10-08 | 1984-10-31 | Glaxo Group Ltd | |
US4811731A (en) | 1985-07-30 | 1989-03-14 | Glaxo Group Limited | Devices for administering medicaments to patients |
JPH0667926B2 (ja) * | 1985-11-12 | 1994-08-31 | 旭化成工業株式会社 | 環状のイソキノリンスルホンアミド誘導体 |
JPH05963A (ja) | 1990-04-13 | 1993-01-08 | Toray Ind Inc | ポリペプチド類組成物 |
US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
IL117149A0 (en) * | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
JP2001172257A (ja) | 1999-10-05 | 2001-06-26 | Fujisawa Pharmaceut Co Ltd | 有機スルホンアミド化合物 |
AR033517A1 (es) * | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
CA2364178C (en) | 2000-12-05 | 2006-01-10 | Yasuhiro Katsu | N-benzenesulfonyl l-proline compounds as bradykinin antagonists |
MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
AU2002247208A1 (en) * | 2001-03-05 | 2002-09-19 | Icos Corporation | Selective pde3b inhibitors and use of the same in therapy |
DE10155684A1 (de) * | 2001-11-13 | 2003-05-22 | Bayer Ag | Thiazolharnstoffe |
JPWO2004069828A1 (ja) * | 2003-02-04 | 2006-05-25 | 三菱ウェルファーマ株式会社 | ピペリジン化合物およびその医薬用途 |
EP1758884A2 (en) * | 2004-05-20 | 2007-03-07 | Elan Pharmaceuticals, Inc. | N-cyclic sulfonamido inhibitors of gamma secretase |
JP5140577B2 (ja) * | 2005-03-31 | 2013-02-06 | タケダ カリフォルニア インコーポレイテッド | ヒドロキシステロイドデヒドロゲナーゼ阻害剤 |
WO2006134481A1 (en) | 2005-06-16 | 2006-12-21 | Pfizer Inc. | Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1 |
WO2007115805A2 (en) * | 2006-04-05 | 2007-10-18 | European Molecular Biology Laboratory (Embl) | Aurora kinase inhibitors |
KR101495611B1 (ko) * | 2006-04-07 | 2015-02-25 | 메틸진 인코포레이티드 | 히스톤 데아세틸라아제의 억제제 |
US8603465B1 (en) * | 2006-08-07 | 2013-12-10 | Merck Sharp & Dohme, Corp. | Methods for treatment of polyposis |
AU2008296479A1 (en) | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis |
JP2011507910A (ja) * | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
EP2283160A4 (en) | 2008-05-07 | 2012-01-04 | Wintherix Llc | METHOD FOR IDENTIFYING WNT SIGNALING MODULATING COMPOUNDS IN CANCER CELLS |
US9623109B2 (en) | 2008-05-27 | 2017-04-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of killing cells and use of same in prevention and treatment of cancer |
TW201028421A (en) * | 2009-01-15 | 2010-08-01 | Abbott Lab | Novel benzenesulfonamides as calcium channel blockers |
EP2714081A4 (en) | 2011-05-27 | 2015-09-09 | Cytocure Llc | METHODS, COMPOSITIONS AND KIT FOR CREAM TREATMENT |
JP2015508644A (ja) | 2012-02-08 | 2015-03-23 | インサイト ジェネティクス インコーポレイテッド | 癌の診断および治療のためのros1の融合体に関する方法および組成物 |
US20130330761A1 (en) | 2012-06-12 | 2013-12-12 | Celcuity, LLC | Whole cell assays and methods |
EP3044218B1 (en) | 2013-09-10 | 2020-05-27 | Board Of Regents Of the University Of Texas System | Therapeutics targeting truncated adenomatous polyposis coli (apc) proteins |
-
2014
- 2014-09-10 EP EP14843412.9A patent/EP3044218B1/en active Active
- 2014-09-10 BR BR112016005252A patent/BR112016005252A2/pt not_active Application Discontinuation
- 2014-09-10 RU RU2016113279A patent/RU2727516C2/ru not_active Application Discontinuation
- 2014-09-10 CA CA2924062A patent/CA2924062C/en active Active
- 2014-09-10 MX MX2016003082A patent/MX2016003082A/es unknown
- 2014-09-10 CN CN201480061472.6A patent/CN105873913B/zh active Active
- 2014-09-10 ES ES14843412T patent/ES2811090T3/es active Active
- 2014-09-10 WO PCT/US2014/054987 patent/WO2015038644A2/en active Application Filing
- 2014-09-10 JP JP2016542070A patent/JP6506291B2/ja active Active
- 2014-09-10 SG SG11201601850YA patent/SG11201601850YA/en unknown
- 2014-09-10 KR KR1020187002519A patent/KR102300576B1/ko active IP Right Grant
- 2014-09-10 DK DK14843412.9T patent/DK3044218T3/da active
- 2014-09-10 KR KR1020167009391A patent/KR101824230B1/ko active IP Right Grant
- 2014-09-10 US US14/482,659 patent/US9856233B2/en active Active
- 2014-09-10 AU AU2014318821A patent/AU2014318821B2/en not_active Ceased
-
2016
- 2016-03-15 ZA ZA2016/01798A patent/ZA201601798B/en unknown
- 2016-11-02 HK HK16112580.3A patent/HK1224291A1/zh unknown
-
2017
- 2017-11-27 US US15/823,150 patent/US10577344B2/en active Active
-
2018
- 2018-04-27 AU AU2018202898A patent/AU2018202898A1/en not_active Abandoned
- 2018-08-01 ZA ZA2018/05172A patent/ZA201805172B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2924062C (en) | 2019-05-14 |
EP3044218A4 (en) | 2017-02-22 |
KR20160049014A (ko) | 2016-05-04 |
ZA201805172B (en) | 2019-08-28 |
RU2016113279A (ru) | 2017-10-16 |
KR20180011890A (ko) | 2018-02-02 |
CN105873913B (zh) | 2019-12-03 |
CA2924062A1 (en) | 2015-03-19 |
ZA201601798B (en) | 2022-05-25 |
ES2811090T3 (es) | 2021-03-10 |
AU2018202898A1 (en) | 2018-05-17 |
HK1224291A1 (zh) | 2017-08-18 |
US20150232444A1 (en) | 2015-08-20 |
US10577344B2 (en) | 2020-03-03 |
DK3044218T3 (da) | 2020-07-27 |
KR102300576B1 (ko) | 2021-09-08 |
JP2016534140A (ja) | 2016-11-04 |
EP3044218A2 (en) | 2016-07-20 |
BR112016005252A2 (pt) | 2017-09-12 |
AU2014318821B2 (en) | 2018-04-19 |
EP3044218B1 (en) | 2020-05-27 |
US9856233B2 (en) | 2018-01-02 |
CN105873913A (zh) | 2016-08-17 |
US20190135776A1 (en) | 2019-05-09 |
JP6506291B2 (ja) | 2019-04-24 |
WO2015038644A3 (en) | 2015-05-14 |
MX2016003082A (es) | 2016-09-13 |
AU2014318821A1 (en) | 2016-04-14 |
ES2811090T8 (es) | 2022-09-29 |
WO2015038644A2 (en) | 2015-03-19 |
KR101824230B1 (ko) | 2018-01-31 |
RU2727516C2 (ru) | 2020-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201805172B (en) | Therapeutics targeting truncated adenomatous polyposis coli (apc) proteins | |
HK1224178A1 (zh) | 環肽作為蛋白質靶向劑 | |
IL245544A0 (en) | drug delivery system | |
EP2948202A4 (en) | WHEEL POSITION COMPENSATION WITH FIELD-ORIENTED CONTROL | |
IL233621A0 (en) | Pyrazole fungicide mixtures | |
EP2961302A4 (en) | MIXING SYSTEM | |
EP3038638A4 (en) | Small cationic anti-biofilm and idr peptides | |
EP3345282A4 (en) | Usb power delivery dead-battery control | |
DK2994154T3 (da) | Antimikrobielt peptid | |
ZA201508015B (en) | Solid forms of fungicidal pyrazoles | |
GB201308917D0 (en) | Delivery | |
HK1208344A1 (en) | Cell-specific targeting using nanostructured delivery systems | |
EP2961447A4 (en) | DIRECT PRESSURE-RELATED INTRAOSSARY CELL THERAPEUTIC RELEASE SYSTEM | |
DK3288955T3 (da) | Bortezomib-baseret afgivelsessystem | |
DE112014004954T8 (de) | Abgabesystem | |
DE112014004938T8 (de) | Abgabesystem | |
HK1220366A1 (zh) | 蛋白製劑 | |
GB201306981D0 (en) | Delivery system | |
GB201304973D0 (en) | Recombinant protein | |
EP3088000A4 (en) | Vaccine targeting il-17a | |
GB201316666D0 (en) | Targeting molecule | |
PL2943067T3 (pl) | Kompozycja grzybobójcza | |
GB201308860D0 (en) | Delivery peptides | |
GB201515841D0 (en) | Improvements relating to message delivery control | |
GB201510182D0 (en) | Improvements in antimicrobial drugs |